8-K: SELLAS Life Sciences Reports Positive Clinical Trial Progress and Third Quarter 2024 Financial Results

SELLAS Life Sciences announced its third quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical trials and regulatory designations.

Summary

• SELLAS Life Sciences reported a net loss of $7.1 million for the third quarter of 2024, an improvement from the $9.3 million loss in the same period of 2023.
• Research and development expenses decreased to $4.4 million in Q3 2024 from $5.8 million in Q3 2023, due to reduced clinical supply purchases and personnel costs.
• General and administrative expenses also decreased to $3.0 million in Q3 2024 from $3.5 million in Q3 2023, primarily due to personnel changes.
• The company's cash and cash equivalents totaled approximately $21 million as of September 30, 2024.
• The Phase 3 REGAL study of galinpepimut-S (GPS) in AML is on track for an interim analysis in Q4 2024.
• Phase 2a data for SLS009 in relapsed/refractory AML after venetoclax failure will be presented at the ASH annual meeting in December.
• The FDA granted Rare Pediatric Disease Designation (RPDD) to GPS for the treatment of pediatric AML.
• SLS009 showed promising results in a Phase 2a study, with 55% of patients achieving a 50% reduction in bone marrow blasts.
• Additional Phase 2 cohorts for SLS009 are continuing enrollment, including specific cohorts for AML with myelodysplasia-related changes.
• Initial safety and efficacy data from the National Institute of Health PIVOT program in pediatric tumors are expected in Q4 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical trial results and reduced losses, but the company is still loss making and has a relatively low cash position. The sentiment is cautiously optimistic.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Research and development expenses have been reduced, suggesting better cost management.
• The company maintains a solid cash position of $21 million.
• The Phase 3 REGAL study is progressing as planned, with an interim analysis expected soon.
• SLS009 demonstrated promising efficacy in a Phase 2a study, with a significant reduction in bone marrow blasts.
• The FDA granted Rare Pediatric Disease Designation to GPS for pediatric AML, potentially opening new market opportunities.
• The company is actively expanding the clinical development of SLS009 with additional Phase 2 cohorts.
• The NIH PIVOT program is progressing, with initial data expected soon.

Negatives

• The company still reported a net loss of $7.1 million for the quarter.
• The company has reduced headcount which may impact future operations.
• The company is still reliant on external funding to continue operations.

Risks

• The company faces risks and uncertainties associated with oncology product development and clinical success.
• Regulatory approval for their products is not guaranteed.
• The company's financial performance is still reliant on external funding.
• The company is subject to risks and uncertainties detailed in their SEC filings.

Future Outlook

The company anticipates significant milestones in the near future, including the interim analysis of the Phase 3 REGAL study, presentation of SLS009 data at ASH, and additional data updates from ongoing clinical trials in the fourth quarter of 2024.

Management Comments

• Angelos Stergiou, MD, ScD h.c., President and CEO of SELLAS, stated that they are excited to announce the updated SLS009 Phase 2a data at ASH in December and to provide topline data from cohorts four and five in patients with relapsed/refractory AML this quarter.
• Management is grateful to the patients, families, investigators, study teams, and employees who have contributed to the Phase 3 REGAL study.
• Management is looking forward to the significant milestones on the horizon, with interim analysis from the Phase 3 REGAL study anticipated in the coming weeks.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on oncology and hematology. The progress of SELLAS's clinical trials and regulatory designations are important for investors and stakeholders in this sector. The focus on novel therapies and targeted treatments aligns with current trends in cancer research and development.

Comparison to Industry Standards

• SELLAS's reduction in R&D and G&A expenses is a positive sign, as many biotech companies struggle with high operating costs, however, the company is still loss making.
• The 55% reduction in bone marrow blasts observed in the SLS009 Phase 2a study is promising, as many similar trials in AML have not shown such high response rates. For example, studies of venetoclax combinations in AML have shown varying response rates, and the results of SLS009 appear to be competitive.
• The FDA's Rare Pediatric Disease Designation for GPS and SLS009 is a significant advantage, as it can lead to expedited review and potential market exclusivity. This is similar to other companies that have received RPDD for their therapies, such as Agios Pharmaceuticals for Tibsovo in pediatric AML.
• The company's cash position of $21 million is relatively low for a late-stage clinical company, and they may need to raise additional capital in the near future. Many similar companies have cash runways of 12-24 months, and SELLAS's cash position may be a concern for investors.

Stakeholder Impact

• Shareholders may view the reduced losses and positive clinical trial results favorably.
• Employees may be impacted by the changes in headcount.
• Patients and their families may benefit from the potential approval of new therapies.
• The company's suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will conduct an interim analysis of the Phase 3 REGAL study in Q4 2024.
• SELLAS will present Phase 2a data for SLS009 at the ASH annual meeting in December.
• The company will continue enrollment in additional Phase 2 cohorts for SLS009.
• Initial safety and efficacy data from the NIH PIVOT program are expected in Q4 2024.

Key Dates

Keywords

SELLAS Life Sciences, AML, GPS, SLS009, Clinical Trials, Rare Pediatric Disease Designation, Immunotherapy, CDK9 inhibitor, Financial Results, Oncology